BIVVOTCinactive

Bioverativ Inc.

Healthcare·Rare Disease·Commercial

Rare DiseaseHematology

Bioverativ Inc. (BIVV): 8 pipeline candidates · 6 clinical trials. Updated within the last hour.

9.6/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health8.8

D/E 0.80 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

8 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Bioverativ Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$436.5M

Quarterly Burn

—

Runway

—

Revenue

$328.7M

Pipeline (8 candidates)

Drug	Phase	Indication
alprolix	Approved	Hemophilia B
bivv 001	Preclinical	Hemophilia A
bivv 002	Preclinical	Hemophilia B
bivv001	Phase 1/Phase 2	Hemophilia A
bivv002	Preclinical	Hemophilia B
bivv009	Phase 3	Primary cold agglutinin disease
eloctate	Approved	Hemophilia A
st-400	Phase 1/Phase 2	Transfusion-dependent beta-thalassemia

6 clinical trials

Frequently asked questions

How many drug candidates are in Bioverativ Inc.'s pipeline?

Bioverativ Inc. (BIVV) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Bioverativ Inc.'s lead drug candidate?

Bioverativ Inc.'s most advanced tracked candidate is alprolix (Approved) for Hemophilia B.

Get the full picture on Bioverativ Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free Analysis Browse Calendar